The Voices of the Ataxia Community - An Introduction to Patient Focused Drug Development

Join NAF and CureDRPLA in learning more about how to participate in the upcoming Externally-Led Patient Focused Drug Development meeting that will focus on Polyglutamine Spinocerebellar Ataxias (SCA), which include SCA 1,2,3,6,7,17, and DRPLA.

This webinar explains the purpose of the upcoming EL-PFDD meeting, discusses background information about the FDA and their role in drug development, and informs viewers about how they can participate in this upcoming meeting. Persons with any form of Ataxia are encouraged to attend.

Speakers: James E. Valentine, J.D., M.H.S. & Larry Bauer, Sr. Regulatory Drug Expert